-
1
-
-
0032881369
-
Childhood, neonatal, and stillborn pemphigus vulgaris
-
Bjarnason B, Flosadottir E. Childhood, neonatal, and stillborn pemphigus vulgaris. Int J Dermatol. 1999;38: 680-688.
-
(1999)
Int J Dermatol
, vol.38
, pp. 680-688
-
-
Bjarnason, B.1
Flosadottir, E.2
-
2
-
-
0025789652
-
Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion
-
Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869-877.
-
(1991)
Cell
, vol.67
, pp. 869-877
-
-
Amagai, M.1
Klaus-Kovtun, V.2
Stanley, J.R.3
-
3
-
-
0030902370
-
Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris
-
Koch PJ, Mahoney MG, Ishikawa H, et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol. 1997;137:1091-1102.
-
(1997)
J Cell Biol
, vol.137
, pp. 1091-1102
-
-
Koch, P.J.1
Mahoney, M.G.2
Ishikawa, H.3
-
4
-
-
0028148708
-
Free recirculation of memory B cells versus antigen-dependent differentiation to antibody-forming cells
-
Bachmann MF, Kundig TM, Odermatt B, et al. Free recirculation of memory B cells versus antigen-dependent differentiation to antibody-forming cells. J Immunol. 1994;153:3386-3397.
-
(1994)
J Immunol
, vol.153
, pp. 3386-3397
-
-
Bachmann, M.F.1
Kundig, T.M.2
Odermatt, B.3
-
5
-
-
0036235410
-
Plasma cells for a lifetime?
-
Manz RA, Radbruch A. Plasma cells for a lifetime? Eur J Immunol. 2002;32:923-927.
-
(2002)
Eur J Immunol
, vol.32
, pp. 923-927
-
-
Manz, R.A.1
Radbruch, A.2
-
6
-
-
16444367429
-
Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants
-
Wenzel J, Bauer R, Bieber T, et al. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol. 2005;85:185-186.
-
(2005)
Acta Derm Venereol
, vol.85
, pp. 185-186
-
-
Wenzel, J.1
Bauer, R.2
Bieber, T.3
-
7
-
-
8744228329
-
Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)
-
Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51:817-819.
-
(2004)
J Am Acad Dermatol
, vol.51
, pp. 817-819
-
-
Morrison, L.H.1
-
8
-
-
2542490336
-
Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations
-
Espana A, Fernandez-Galar M, Lloret P, et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004;50:974-976.
-
(2004)
J Am Acad Dermatol
, vol.50
, pp. 974-976
-
-
Espana, A.1
Fernandez-Galar, M.2
Lloret, P.3
-
9
-
-
9144262314
-
Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)
-
Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140: 91-96.
-
(2004)
Arch Dermatol
, vol.140
, pp. 91-96
-
-
Dupuy, A.1
Viguier, M.2
Bedane, C.3
-
10
-
-
0041349378
-
Anti-CD20 monoclonal anti-body (rituximab) in the treatment of autoimmune diseases, successful result in refractory pemphigus vulgaris: Report of a case
-
Virgolini L, Marzocchi V. Anti-CD20 monoclonal anti-body (rituximab) in the treatment of autoimmune diseases, successful result in refractory pemphigus vulgaris: report of a case. Hoematologica. 2003;88:ELT24.
-
(2003)
Hoematologica
, vol.88
-
-
Virgolini, L.1
Marzocchi, V.2
-
11
-
-
0037707715
-
Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab)
-
Cooper HL, Healy E, Theaker JM, et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol. 2003;28:366-368.
-
(2003)
Clin Exp Dermatol
, vol.28
, pp. 366-368
-
-
Cooper, H.L.1
Healy, E.2
Theaker, J.M.3
-
12
-
-
0344406066
-
Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)
-
Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003;148:602-603.
-
(2003)
Br J Dermatol
, vol.148
, pp. 602-603
-
-
Herrmann, G.1
Hunzelmann, N.2
Engert, A.3
-
13
-
-
0036827616
-
Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder
-
Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002;47:785-788.
-
(2002)
J Am Acad Dermatol
, vol.47
, pp. 785-788
-
-
Salopek, T.G.1
Logsetty, S.2
Tredget, E.E.3
-
14
-
-
0028108050
-
CD20: A regulator of cell-cycle progression of B lymphocytes
-
Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15: 450-454.
-
(1994)
Immunol Today
, vol.15
, pp. 450-454
-
-
Tedder, T.F.1
Engel, P.2
-
15
-
-
0035205004
-
Pathophysiology and therapy of pemphigus in the 21st century
-
Stanley JR. Pathophysiology and therapy of pemphigus in the 21st century. J Dermatol. 2001;28:645-646.
-
(2001)
J Dermatol
, vol.28
, pp. 645-646
-
-
Stanley, J.R.1
-
16
-
-
0033911628
-
Patterns of remission in pemphigus vulgaris
-
Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42:422-427.
-
(2000)
J Am Acad Dermatol
, vol.42
, pp. 422-427
-
-
Herbst, A.1
Bystryn, J.C.2
-
17
-
-
0345724922
-
Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris
-
Mimouni D, Nousari CH, Cummins DL, et al. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol. 2003;49:1059-1062.
-
(2003)
J Am Acad Dermatol
, vol.49
, pp. 1059-1062
-
-
Mimouni, D.1
Nousari, C.H.2
Cummins, D.L.3
-
18
-
-
0023723595
-
Plasmapheresis therapy of pemphigus
-
Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol. 1988;124:1702-1704.
-
(1988)
Arch Dermatol
, vol.124
, pp. 1702-1704
-
-
Bystryn, J.C.1
-
19
-
-
0023148121
-
Azathioprine in the treatment of pemphigus vulgaris. a long-term follow-up
-
Aberer W, Wolff-Schreiner EC, Stingl G, et al. Azathioprine in the treatment of pemphigus vulgaris. a long-term follow-up. J Am Acad Dermatol. 1987;16(3 pt 1): 527-533.
-
(1987)
J Am Acad Dermatol
, vol.16
, Issue.3 PART 1
, pp. 527-533
-
-
Aberer, W.1
Wolff-Schreiner, E.C.2
Stingl, G.3
-
20
-
-
85047692468
-
Pemphigus vulgaris. combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine
-
Fine JD, Appell ML, Green LK, et al. Pemphigus vulgaris. combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol. 1988;124:236-239.
-
(1988)
Arch Dermatol
, vol.124
, pp. 236-239
-
-
Fine, J.D.1
Appell, M.L.2
Green, L.K.3
-
21
-
-
0023413360
-
Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris
-
Euler HH, Loffler H, Christophers E. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris. Arch Oermatol. 1987;123: 1205-1210.
-
(1987)
Arch Oermatol
, vol.123
, pp. 1205-1210
-
-
Euler, H.H.1
Loffler, H.2
Christophers, E.3
-
22
-
-
0035977173
-
Rituximab: Mechanisms and applications
-
Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer. 2001;85:1619-1623.
-
(2001)
Br J Cancer
, vol.85
, pp. 1619-1623
-
-
Johnson, P.W.1
Glennie, M.J.2
-
23
-
-
0036822286
-
An open study of B lymphocyte depletion in systemic lupus erythematosus
-
Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46: 2673-2677.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 2673-2677
-
-
Leandro, M.J.1
Edwards, J.C.2
Cambridge, G.3
-
24
-
-
0344824642
-
Novel therapies in pediatric rheumatic disease
-
Chira P, Sandborg CI. Novel therapies in pediatric rheumatic disease. Curr Opin Pediatr. 2003;15: 579-585.
-
(2003)
Curr Opin Pediatr
, vol.15
, pp. 579-585
-
-
Chira, P.1
Sandborg, C.I.2
-
25
-
-
0014986054
-
Correlation of pemphigoid and pemphigus antibody titers with activity of disease
-
Sams WM Jr, Jordon RE. Correlation of pemphigoid and pemphigus antibody titers with activity of disease. Br J Dermatol 1971;84:7-13.
-
(1971)
Br J Dermatol
, vol.84
, pp. 7-13
-
-
Sams Jr, W.M.1
Jordon, R.E.2
-
26
-
-
0037318312
-
Entero-viral meningoencephalitis after anti-CD20 (rituximab) treatment
-
Epub January 16
-
Quartier P, Toumilhac O, Archimbaud C, et al. Entero-viral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis. 2003;36:e47-e49. Epub January 16, 2003.
-
(2003)
Clin Infect Dis. 2003
, vol.36
-
-
Quartier, P.1
Toumilhac, O.2
Archimbaud, C.3
-
27
-
-
0037926853
-
Rituximab for the treatment of refractory autoimmune hemolytic anemia in children
-
Epub January 16
-
Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857-3861. Epub January 16, 2003.
-
(2003)
Blood. 2003
, vol.101
, pp. 3857-3861
-
-
Zecca, M.1
Nobili, B.2
Ramenghi, U.3
-
28
-
-
38849196629
-
-
Rituxan [package insert, South San Francisco, Calif: Genentech, Inc; 2007
-
Rituxan [package insert]. South San Francisco, Calif: Genentech, Inc; 2007.
-
-
-
-
30
-
-
0141813574
-
Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2
-
Golay J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica. 2003;88:1002-1012.
-
(2003)
Haematologica
, vol.88
, pp. 1002-1012
-
-
Golay, J.1
Manganini, M.2
Facchinetti, V.3
-
31
-
-
0042346042
-
Complement activation determines the therapeutic activity of rituximab in vivo
-
Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171:1581-1587.
-
(2003)
J Immunol
, vol.171
, pp. 1581-1587
-
-
Di Gaetano, N.1
Cittera, E.2
Nota, R.3
-
32
-
-
0029016147
-
Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells
-
Kanzaki M, Shibata H, Mogami H, et al. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem. 1995;270:13099-13104.
-
(1995)
J Biol Chem
, vol.270
, pp. 13099-13104
-
-
Kanzaki, M.1
Shibata, H.2
Mogami, H.3
-
33
-
-
0022202908
-
The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle
-
Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol. 1985;135: 3795-3801.
-
(1985)
J Immunol
, vol.135
, pp. 3795-3801
-
-
Golay, J.T.1
Clark, E.A.2
Beverley, P.C.3
-
34
-
-
0033067232
-
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
-
Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999;17:1851-1857.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1851-1857
-
-
Davis, T.A.1
White, C.A.2
Grillo-Lopez, A.J.3
-
35
-
-
33644830710
-
Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)
-
Kong HH, Prose NS, Ware RE, et al. Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol. 2005;22:461-464.
-
(2005)
Pediatr Dermatol
, vol.22
, pp. 461-464
-
-
Kong, H.H.1
Prose, N.S.2
Ware, R.E.3
|